New hope for PAH patients: rapid treatment aims to reverse heart damage
NCT ID NCT05203510
First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study tests whether quickly starting and increasing a medication called treprostinil can improve right heart function and reverse damage in people with pulmonary arterial hypertension (PAH). The study enrolled 52 adults with confirmed PAH. Researchers will measure changes in heart function using MRI and other tests over 12 to 36 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Banner University Medical Center (University of Arizona)
Phoenix, Arizona, 85006, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Carilion Clinic
Roanoke, Virginia, 24014, United States
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Community Health Network
Indianapolis, Indiana, 46219, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Georgia Clinical Research
Austell, Georgia, 30106, United States
-
Hartford Hospital
Hartford, Connecticut, 06106, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
HonorHealth John C. Lincoln Medical Center
Phoenix, Arizona, 85020, United States
-
Indiana University Health North Hospital
Indianapolis, Indiana, 46202, United States
-
Integris Baptist Medical Center
Oklahoma City, Oklahoma, 73112, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Oklahoma Heart Institute
Tulsa, Oklahoma, 74104, United States
-
Prisma Health
Greenville, South Carolina, 29605, United States
-
Temple Hospital
Philadelphia, Pennsylvania, 19140, United States
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
USF
Tampa, Florida, 33606, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
University of California San Francisco - Fresno
Fresno, California, 93701, United States
-
University of California San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine
San Francisco, California, 94143, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Rochester Medical Center
Rochester, New York, 14623, United States
Conditions
Explore the condition pages connected to this study.